Use of the terminal complement inhibitor eculizumab in paediatric heart transplant recipients

Yuk M. Law*, Deipanjan Nandi, Kimberly Molina, Katheryn Gambetta, Kevin P. Daly, Bibhuti Das

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

Antibody-mediated rejection is a major clinical challenge that limits graft survival. Various modalities of treatment have been reported in small studies in paediatric heart recipients. A novel approach is to use complement-inhibiting agents, such as eculizumab, which inhibits cleavage of C5 to C5a thereby limiting the formation of membrane attack complex and terminal complement-mediated injury of tissue-bound antibodies. This medical modality of treatment has theoretical advantages but the collective experience in its use in the solid organ transplant community remains small. We add to this experience by combining 14 cases from 6 paediatric heart centres in this descriptive study.

Original languageEnglish (US)
Pages (from-to)107-113
Number of pages7
JournalCardiology in the young
Volume30
Issue number1
DOIs
StatePublished - 2020

Keywords

  • Heart transplantation
  • antiboby-mediated rejection
  • children
  • eculizumab
  • medical therapy
  • paediatrics

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Use of the terminal complement inhibitor eculizumab in paediatric heart transplant recipients'. Together they form a unique fingerprint.

  • Cite this